Porton Pharma Solutions
Porton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO), is headquartered in China (CN) and operates extensively across Asia, Europe, and North America. Founded in 2003, the company has established itself as a key player in the pharmaceutical and biotechnology sectors, specialising in the development and production of complex drug formulations, including injectables and biologics. With a commitment to innovation and quality, Porton Pharma offers a comprehensive range of services, from preclinical development to commercial manufacturing. Their state-of-the-art facilities and adherence to stringent regulatory standards set them apart in the industry. Notably, Porton Pharma has achieved significant milestones, including successful partnerships with global pharmaceutical companies, reinforcing its position as a trusted provider in the market.
DitchCarbon Score
How does Porton Pharma Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Porton Pharma Solutions's score of 7 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Porton Pharma Solutions's reported carbon emissions
In 2022, Porton Pharma Solutions reported total carbon emissions of approximately 105,616,610 kg CO2e, comprising about 20,121,610 kg CO2e from Scope 1 emissions and about 85,495,000 kg CO2e from Scope 2 emissions. This marked a reduction from 2021, where total emissions were about 94,360,850 kg CO2e, indicating a positive trend in their emissions management. The company has committed to near-term reduction targets, although specific numerical goals have not been disclosed. Notably, Porton Pharma Solutions has not yet committed to a net-zero target. The organisation operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in China. Porton Pharma Solutions is actively working towards reducing its carbon footprint, reflecting a growing commitment to sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 26,761,250 | 00,000,000 |
| Scope 2 | 67,599,610 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Porton Pharma Solutions is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
